These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
440 related articles for article (PubMed ID: 18381447)
1. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Fuchs BC; Fujii T; Dorfman JD; Goodwin JM; Zhu AX; Lanuti M; Tanabe KK Cancer Res; 2008 Apr; 68(7):2391-9. PubMed ID: 18381447 [TBL] [Abstract][Full Text] [Related]
2. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Thomson S; Buck E; Petti F; Griffin G; Brown E; Ramnarine N; Iwata KK; Gibson N; Haley JD Cancer Res; 2005 Oct; 65(20):9455-62. PubMed ID: 16230409 [TBL] [Abstract][Full Text] [Related]
3. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436 [TBL] [Abstract][Full Text] [Related]
4. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342 [TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799 [TBL] [Abstract][Full Text] [Related]
6. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062 [TBL] [Abstract][Full Text] [Related]
7. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Yauch RL; Januario T; Eberhard DA; Cavet G; Zhu W; Fu L; Pham TQ; Soriano R; Stinson J; Seshagiri S; Modrusan Z; Lin CY; O'Neill V; Amler LC Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8686-98. PubMed ID: 16361555 [TBL] [Abstract][Full Text] [Related]
8. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Kim CH; Lee JC Lung Cancer; 2009 Feb; 63(2):219-26. PubMed ID: 18599154 [TBL] [Abstract][Full Text] [Related]
9. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164 [TBL] [Abstract][Full Text] [Related]
11. Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Troussard AA; McDonald PC; Wederell ED; Mawji NM; Filipenko NR; Gelmon KA; Kucab JE; Dunn SE; Emerman JT; Bally MB; Dedhar S Cancer Res; 2006 Jan; 66(1):393-403. PubMed ID: 16397254 [TBL] [Abstract][Full Text] [Related]
12. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. Höpfner M; Sutter AP; Huether A; Schuppan D; Zeitz M; Scherübl H J Hepatol; 2004 Dec; 41(6):1008-16. PubMed ID: 15582135 [TBL] [Abstract][Full Text] [Related]
13. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Li B; Chang CM; Yuan M; McKenna WG; Shu HK Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544 [TBL] [Abstract][Full Text] [Related]
14. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines. Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520 [TBL] [Abstract][Full Text] [Related]
15. Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR/Akt/IκBβ/NF-κB pathway. Li T; Dong ZR; Guo ZY; Wang CH; Zhi XT; Zhou JW; Li DK; Chen ZT; Chen ZQ; Hu SY Liver Int; 2015 Apr; 35(4):1416-29. PubMed ID: 25066210 [TBL] [Abstract][Full Text] [Related]
16. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Buck E; Eyzaguirre A; Rosenfeld-Franklin M; Thomson S; Mulvihill M; Barr S; Brown E; O'Connor M; Yao Y; Pachter J; Miglarese M; Epstein D; Iwata KK; Haley JD; Gibson NW; Ji QS Cancer Res; 2008 Oct; 68(20):8322-32. PubMed ID: 18922904 [TBL] [Abstract][Full Text] [Related]
17. The role of CD29-ILK-Akt signaling-mediated epithelial-mesenchymal transition of liver epithelial cells and chemoresistance and radioresistance in hepatocellular carcinoma cells. Jiang X; Wang J; Zhang K; Tang S; Ren C; Chen Y Med Oncol; 2015 May; 32(5):141. PubMed ID: 25805567 [TBL] [Abstract][Full Text] [Related]
18. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma. Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130 [TBL] [Abstract][Full Text] [Related]